NEW YORK, Aug. 18, 2014 /PRNewswire/ --
Lifshitz & Miller announces that a class action was filed in the United States District Court for the Southern District of Indiana alleging that Endocyte, Inc. ("ECYT") issued false and misleading statements between March 21, 2014 and May 2, 2014. Specifically, on May 2, 2014, Endocyte disclosed that VYNFINIT was found ineffective in the treatment of platinum-resistant ovarian cancer, based on certain testing methods known as response evaluation criteria in solid tumors, or "RECIST."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts